Alembic's Bosutinib Approval & Market Opportunity

  Published 10 months ago

Alembic Pharmaceuticals received USFDA approval for Bosutinib tablets, a generic equivalent to Bosulif, targeting a $291 million market. Alembic boasts 223 total ANDA approvals and strong R&D/manufacturing capabilities.

  • ANDA approved for Bosutinib, treating CML.
  • $291M US market size (ending March 2025).
  • Alembic: 223 USFDA approvals to date.

You might like these

India Growth Boost Amid US Tariffs

Yes Bank: Funding & SMBC Acquisition News

Baidu Launches AI Video Generator & Search Upgrade

Oil India Forms Fertilizer JV

HLE Glascoat Acquires Omeras, Expands Tank Market

TVS Motor August 2025 Growth

Sterlite Tech Launches Next-Gen Data Center Solutions

News that matters the most ⚡